PROGYNOVA 1 mg AND 2 mg TABLETS
(and dosage form):
PROGYNOVA 1 mg AND 2 mg TABLETS
For estrogen therapy of climacteric
complaints in the postmenopause
Progynova tablets contain estradiol valerate (estra-1,3,5(10)-triene-3,17beta-diol 17-valerate) 1,0 mg and 2,0 mg respectively.
A. 21.8.1 Estrogens.
Progynova contains estradiol valerate, an ester of the endogenous female estrogen, which following regular oral administration eliminates the characteristic estrogen deficiency symptoms in the postmenopause or after oophorectomy or radiological castration for non-carcinomatous diseases.
Climacteric complaints after the cessation of monthly bleeding or deficiency symptoms after oophorectomy or radiological castration for non-carcinomatous diseases, such as hot flushes, outbreaks of sweat, sleep disturbances, depressive moods, irritability, headaches, dizziness, bladder irritation, signs of muco-cutaneous involution.
Pregnancy; severe disturbances of liver function; jaundice or persistent itching during a previous pregnancy; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours; existing or previous thromboembolic processes (eg stroke, myocardial infarction); sickle-cell anaemia; existing or suspected hormone-dependent tumours of the uterus or mammae; endometriosis; severe diabetes with vascular changes; congenital disturbances of lipometabolism; otosclerosis with deterioration in previous pregnancies.
DOSAGE AND DIRECTIONS FOR USE
Before starting Progynova a thorough general medical and gynaecological examination (including the breasts) should be carried out.
Unless otherwise prescribed by the doctor, 1 tablet Progynova 2 mg is taken daily after a meal. The tablets are to be swallowed whole with some liquid. After each 21-day regimen there must be a pause in tablet-taking of at least 1 week.
In the course of treatment, the doctor may decide to reduce the dose to 1 tablet Progynova 1 mg daily.
Under this lower dose, too, a tablet-free interval of at least 1 week should be observed after each 21-day regimen.
As a general rule, Progynova treatment should be discontinued every 6 months in order to verify the persistence of complaints requiring treatment.
SIDE EFFECTS AND SPECIAL PRECAUTIONS
A feeling of tension in the breasts, gastric upsets, nausea and vomiting, headaches, increase in body weight, and uterine bleeding can occur.
The doctor should be informed if other medical preparations are taken regularly (eg barbiturates, phenylbutazone, hydantoins, rifampicin, ampicillin) since they can impair the action of Progynova.
If uterine bleeding occurs, the patient must consult her doctor in order to clarify the cause.
Gynaecological check-ups should be carried out at about 6-month intervals.
The doctor should be informed if the patient suffers from the following disorders: diabetes, high blood pressure, varicose veins, otosclerosis, multiple sclerosis, epilepsy, porphyria, tetany, chorea minor. In all these cases, and also where there is a history of phlebitis, strict medical supervision is necessary.
Not for use during pregnancy.
An increased incidence of endometrial uterine carcinoma, related to the continuous use of estrogens in the postmenopausal period has been reported. Since this suspected risk cannot be entirely ruled out, endometrial hyperplasia should be avoided in unopposed estrogen treatment, eg by the additional administration of a progestogen. It is in any case essential to adhere to the dosage scheme prescribed by the doctor, including the instructions regarding tablet-free intervals and length of treatment, and to keep the appointments made for gynaecological check-ups.
In rare cases benign and in even rarer cases malignant liver tumours leading in isolated cases to life-threatening intraabdominal haemorrhage have been observed after the use of hormonal substances such as the one contained in Progynova. If severe upper abdominal complaints, liver enlargement or signs of intraabdominal haemorrhage occur, a liver tumour should be included in the differential-diagnostic considerations and, if necessary, the preparation withdrawn.
Reasons for the immediate discontinuation of Progynova
Occurrence for the first time of migrainous headaches or more frequent occurrence of unusually severe headaches; sudden perceptual disorders (eg disturbances of vision or hearing); first signs of thrombophlebitis or thromboembolic symptoms (for example unusual pains in or swelling of the legs; stabbing pains on breathing or coughing for no apparent reason); a feeling of pain and tightness in the chest; pending operations (six weeks beforehand) and immobilisation, for instance following accidents; onset of jaundice; onset of hepatitis; itching of the whole body; increase in epileptic seizures; significant rise in blood pressure.
Estradiol and other estrogens may cause amenorrhoea, depression, dizziness, gynaecomastia (main side effect in the male), hypercalcaemia (if used in metastatic conditions such as breast cancer), nitrogen retention, oedema, skin rashes, sodium retention, and alterations in liver function.
High doses of estrogens may cause premature closure of epiphysis and depression of malignant neoplasms while low doses may stimulate the growth of malignant neoplasms.
KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
See "Side effects and special precautions". Symptomatic treatment according to conventional methods.
Progynova 1 mg: Beige, lustrous coated tablets.
Progynova 2 mg: Blue, lustrous coated tablets.
Progynova 1 mg: Blister packs of 21 coated tablets.
Progynova 2 mg: Blister packs of 21 coated tablets.
Store below 30°C. For shelf-life, refer to imprint on the pack. Keep out of reach of children.
Progynova 1 mg: B/21.8.1/16
Progynova 2 mg: G.2981 (Act 101/1965)
NAME AND BUSINESS ADDRESS OF THE APPLICANT
Schering (Pty) Ltd
(Reg No: 1964/009072/07)
106 Sixteenth Road
P O Box 5278
Halfway House 1685
DATE OF PUBLICATION OF THIS PACKAGE INSERT
20 September 1982
SCHERING (PTY) LTD
(Reg No: 1964/009072/07)
Schering AG Germany
Updated on this site: April 2003
Current: January 2005
Source: Pharmaceutical Industry
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
Information presented by Malahyde Information Systems © Copyright 1996-2005